[go: up one dir, main page]

AR065864A1 - COMPOSITE OF OXI-CICLOHEXIL-PIPERIDINIL-DIHIDRO-BENZIMIDAZOL-2-ONA PHARMACEUTICAL COMPOSITION THAT IS INCLUDED IN ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT AND INTERMEDIARY COMPOUNDS FOR PREPARATION - Google Patents

COMPOSITE OF OXI-CICLOHEXIL-PIPERIDINIL-DIHIDRO-BENZIMIDAZOL-2-ONA PHARMACEUTICAL COMPOSITION THAT IS INCLUDED IN ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT AND INTERMEDIARY COMPOUNDS FOR PREPARATION

Info

Publication number
AR065864A1
AR065864A1 ARP080101269A ARP080101269A AR065864A1 AR 065864 A1 AR065864 A1 AR 065864A1 AR P080101269 A ARP080101269 A AR P080101269A AR P080101269 A ARP080101269 A AR P080101269A AR 065864 A1 AR065864 A1 AR 065864A1
Authority
AR
Argentina
Prior art keywords
preparation
alkyl
optionally substituted
group
fluorine atoms
Prior art date
Application number
ARP080101269A
Other languages
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38050489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065864(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR065864A1 publication Critical patent/AR065864A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuesto de oxi-ciclohexil-piperidinil-dihidro-benzimidazol-2-ona caracterizado por la formula (1) o una sal del mismo: en la qué: R4 se selecciona entre el grupo que consiste en hidrogeno y fluor R5 se selecciona entre el grupo que consiste enhidrogeno, ciano, halogeno, alquilo C1-6 (opcionalmente sustituido con uno o más átomos de fluor) y alcoxi C1-6 (opcionalmente sustituido con uno o más átomos de fluor) R6 se selecciona entre el grupo que consiste en hidrogeno, halogeno, ciano,alquilo C1-6 (opcionalmente sustituido con uno o más átomos de fluor), alquilsulfonilo C1-6, cicloalquilo C3-6 (opcionalmente sustituido con uno o más átomos de fluor) y alcoxi C1-6 (opcionalmente sustituido con uno o más átomos de fluor); n seselecciona entre 2, 3 y 4 Q se selecciona entre el grupo que consiste en hidrogeno y alquilo C1-6 y R se selecciona entre el grupo que consiste en alquilo C1-6, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-6 y alquinilo C2-6, estando cualquiergrupo alquilo o cicloalquilo opcionalmente sustituido con uno o más átomos de fluor. Composicion farmacéutica que lo comprende. Uso de dicho compuesto para la preparacion de un medicamento util para el tratamiento de una afeccion donde serábeneficioso el agonismo de un receptor muscarínico M1, como ser para el tratamiento de un trastorno psicotico o un deterioro cognitivo. Compuestos intermedios para la preparacion de dicho compuesto.Compound of oxy-cyclohexyl-piperidinyl-dihydro-benzimidazol-2-one characterized by the formula (1) or a salt thereof: in which: R4 is selected from the group consisting of hydrogen and fluorine R5 is selected from the group consisting of hydrogen, cyano, halogen, C1-6 alkyl (optionally substituted with one or more fluorine atoms) and C1-6 alkoxy (optionally substituted with one or more fluorine atoms) R6 is selected from the group consisting of hydrogen, halogen, cyano, C1-6 alkyl (optionally substituted with one or more fluorine atoms), C1-6 alkylsulfonyl, C3-6 cycloalkyl (optionally substituted with one or more fluorine atoms) and C1-6 alkoxy (optionally substituted with one or more fluorine atoms); n is selected from 2, 3 and 4 Q is selected from the group consisting of hydrogen and C1-6 alkyl and R is selected from the group consisting of C1-6 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1 alkyl -6 and C2-6 alkynyl, any alkyl or cycloalkyl group being optionally substituted with one or more fluorine atoms. Pharmaceutical composition that includes it. Use of said compound for the preparation of a medicament useful for the treatment of a condition where agonism of an M1 muscarinic receptor will be beneficial, such as for the treatment of a psychotic disorder or cognitive impairment. Intermediate compounds for the preparation of said compound.

ARP080101269A 2007-03-29 2008-03-27 COMPOSITE OF OXI-CICLOHEXIL-PIPERIDINIL-DIHIDRO-BENZIMIDAZOL-2-ONA PHARMACEUTICAL COMPOSITION THAT IS INCLUDED IN ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT AND INTERMEDIARY COMPOUNDS FOR PREPARATION AR065864A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0706167.4A GB0706167D0 (en) 2007-03-29 2007-03-29 Compounds

Publications (1)

Publication Number Publication Date
AR065864A1 true AR065864A1 (en) 2009-07-08

Family

ID=38050489

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101269A AR065864A1 (en) 2007-03-29 2008-03-27 COMPOSITE OF OXI-CICLOHEXIL-PIPERIDINIL-DIHIDRO-BENZIMIDAZOL-2-ONA PHARMACEUTICAL COMPOSITION THAT IS INCLUDED IN ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT AND INTERMEDIARY COMPOUNDS FOR PREPARATION

Country Status (6)

Country Link
AR (1) AR065864A1 (en)
CL (1) CL2008000865A1 (en)
GB (1) GB0706167D0 (en)
PE (1) PE20090553A1 (en)
TW (1) TW200901979A (en)
WO (1) WO2008119721A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288412B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US8283364B2 (en) 2005-09-30 2012-10-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US8288413B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
EP2194982A1 (en) 2007-09-20 2010-06-16 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
GB0718415D0 (en) 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0786997A4 (en) * 1994-10-27 1998-03-11 Merck & Co Inc Muscarine antagonists
WO1997016186A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine agonists
EP1221443B1 (en) * 1999-10-13 2004-09-01 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
AU2003245565B2 (en) * 2002-06-17 2008-01-03 Banyu Pharmaceutical Co., Ltd. Ophthalmic compositions for treating ocular hypertension
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0605786D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0605784D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
WO2008119721A1 (en) 2008-10-09
GB0706167D0 (en) 2007-05-09
CL2008000865A1 (en) 2008-10-03
PE20090553A1 (en) 2009-06-06
TW200901979A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
AR059977A1 (en) CYCLOHEXIL PIPERIDINIL DIHIDROBENZIMIDAZOL COMPOSITION PHARMACEUTICAL COMPOSITION INCLUDED IN ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT PROCESS FOR PREPARATION AND INTERMEDIARY COMPOUND FOR THE SYNTHESIS OF THE SAME
PE20170899A1 (en) 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS GPR MODULATORS 139
AR064736A1 (en) GPCR AGONISTS
AR071203A1 (en) TRIFLUOROMETIL-INDOL-CARBOXAMIDE COMPOSITE, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF A PSYCHOTIC DISORDER OR COGNITIVE DETERIORATION AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
AR056103A1 (en) COMPOUNDS OF (PIRAN-PIPERIDINIL) BENZIMIDAZOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, PREPARATION PROCESS AND USES IN THE TREATMENT OF AFFECTIONS MEDIATED BY AGONISTS OF MUSCARINIC RECEIVER M1
AR076171A1 (en) PIRAZOLOPIRIMIDINONES 1.6-DISUSTITUIDAS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ALZHEIMER, EPILEPSY AND OTHER DISEASES OF THE CENTRAL NERVOUS SYSTEM.
CL2009000650A1 (en) Compounds derived from amino-pyrazine, kinase-pi 3 inhibitors; pharmaceutical composition; and use for the treatment of inflammatory or allergic conditions, such as respiratory diseases, rheumatoid arthritis, ulcerative colitis, among others.
ECSP088210A (en) SUBSTITUTED BENCIMIDAZOLS AND PREPARATION METHODS
CL2012002771A1 (en) Compounds of substituted aryletinyl, modulators of mglur5 receptors; obtaining process; pharmaceutical composition; and its use in the treatment or prevention of schizophrenia, cognitive diseases, x fragile syndrome or autism.
PE20150230A1 (en) NEW DIAZAESPIROCICLOALKANOS AND AZAESPIROCICLOALKANOS
DOP2009000133A (en) DERIVATIVES OF INDOL AS AGONISTS OF S1P1 RECEIVERS
ECSP10010722A (en) ORGANIC COMPOUNDS
CL2014001280A1 (en) Compounds derived from substituted 4-phenyl-pyridines, modulators of the nk1 receptor; preparation procedure; pharmaceutical composition; and its use in the treatment of emesis, bladder dysfunction, depression or anxiety
PE20170666A1 (en) 2- (MORFOLIN-4-IL) -1,7-NAPHTHYRIDINES
UY32409A (en) FUSIONED RING COMPOUND AND ITS USE
AR068369A1 (en) N4 XINAFOATE SALT - [(2,2-DIFLUOR-4H-BENZO [1,4] OXAZIN-3-ON) -6-IL] -5-FLUOR-N2- [3- (METHYLAMINOCARBONYLMETHYLENE) -FENYL] 2 , 4-PYRIMIDINDIAMINE "
AR059957A1 (en) DERIVATIVES OF SPIROINDOLINONE, METHODS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CANCER.
CL2008000641A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED AMIDAS; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF INSOMNIUM, SEXUAL DYSFUNCTION, SCHIZOPHRENIA, BETWEEN OTHER SICK
CL2008002295A1 (en) Alkylsulfonyl-substituted thiazolid derivative compounds; pharmaceutical composition; and use for the treatment of hepatitis c.
CL2013003527A1 (en) Heterocyclic antagonist compounds of muscarinic receptors and agonists of the beta2 adrenergic receptor; its pharmaceutical composition; its combination; a device and its use in the prevention and / or treatment of broncho-obstructive or inflammatory diseases such as asthma and epoc.
CL2012001366A1 (en) Carboxamida
PE20160664A1 (en) HETEROAROMATIC COMPOUNDS AND THEIR USE AS D1 LIGANDS OF DOPAMINE
CO6321245A2 (en) GLUCOCORTICOID MIMETICS METHODS FOR THEIR MANUFACTURING PHARMACEUTICAL COMMITMENTS AND USE OF THE SAME
EA201101116A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING 2-OXO-1-PYRROLIDINE DERIVATIVES
CL2011001331A1 (en) Nalmefene Hydrochloride Dihydrate; methods for its preparation; pharmaceutical composition comprising it; and use for the treatment of alcoholism.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal